2016-02-24T14:02:29-06:00 2015-06-30 860683059 BEACHFLEISCHMAN PC PO BOX 64130 TUCSON AZ 857284130 990 2014-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 STEVEN BROADBENT MBA COO 5205473440 2016-02-18 1 KAREN K MCCLOSKEY CPA P00099644 5203214600 2014 2016-08-17 19:52:53Z MARTHA BRUMFIELD PHD 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 14068793 0 X WWW.C-PATH.ORG X 2004 AZ CREATE AND MANAGE INTERNATIONAL COLLABORATIONS TO RESOLVE PROBLEMS AND DEVELOP NOVEL TOOLS, ENABLING THE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS. 16 15 49 16 0 0 5370782 10269810 3007261 3715780 -13826 13987 52598 69216 8416815 14068793 293808 3684743 0 0 4027055 4934299 0 0 14138 3713997 4558896 8034860 13177938 381955 890855 15253096 15716704 11359520 10932273 3893576 4784431 X THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. 0 0 11136489 3684743 3715780 THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO IMPLEMENTING THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA) THE REGULATED (MEDICAL PRODUCT INDUSTRY), ACADEMIA, PATIENTS ORGANIZATIONS, AND OTHER ORGANIZATIONS THAT RESULT IN ACCELERATED DEVELOPMENT OF SAFE, NEW MEDICAL PRODUCTS, AND SERVES AS A RESOURCE TO CONGRESS. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE:THE COALITION AGAINST MAJOR DISEASES (CAMD) DEVELOPS TOOLS AND PROCESSES TO ACCELERATE PROGRESS IN THE PREVENTION, TREATMENT AND CURE OF MAJOR NEURODEGENERATIVE DISEASES, INITIALLY FOCUSING ON ALZHEIMER'S AND PARKINSON'S DISEASES. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: 1) ENHANCING ITS PUBLIC DATABASE OF ALZHEIMER'S DISEASE CLINICAL TRIALS AVAILABLE FOR RESEARCH. 2) DISTRIBUTING AND EDUCATING USERS ON ITS DISEASE PROGRESSION MODEL CREATED FROM USE OF THE DATA FROM THE DATABASE, AND DATA FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE STUDIES. 3) PROGRESSING THE DEVELOPMENT ON A SERIES OF CEREBRAL SPINAL FLUID (CSF) AND HIPPOCAMPAL IMAGING BIOMARKERS FOR USE IN IDENTIFYING EARLY SYMPTOMATIC PATIENTS WITH A HIGH LIKELIHOOD OF PROGRESSION TO DEMENTIA IN A SHORT PERIOD OF TIME. TWO LETTERS OF SUPPORT WERE ISSUED BY THE FDA TO ENCOURAGE EXPLORATORY USE OF THESE BIOMARKERS IN ALZHEIMER'S DISEASE CLINICAL TRIALS. 4) A LETTER OF INTENT WAS SUBMITTED TO THE EMA TO QUALIFY DOPAMINE TRANSPORTER NEUROIMAGING FOR ENRICHMENT IN PARKINSON'S DISEASE TRIALS. A LETTER OF SUPPORT WAS ISSUED BY THE FDA SUPPORTING THIS BIOMARKER IN EXPLORATORY USE IN CLINICAL TRIALS FOR PARKINSON'S DISEASE. 5) WORKED PROGRESSED TOWARD DEVELOPING AND QUALIFYING AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR EARLY STAGES OF ALZHEIMER'S DISEASE. THIS EFFORT WAS ULTIMATELY HALTED DUE TO THE FAILURE TO SHOW SIGNIFICANT IMPROVEMENT OVER CURRENT ASSESSMENT INSTRUMENTS. 6) EFFORTS ARE UNDERWAY TO LAUNCH A NEW CONSORTIUM DEDICATED TO DEVELOPING NEW DRUG DEVELOPMENT TOOLS FOR USE IN DEVELOPING, TESTING, AND THE REGULATORY REVIEW OF NEW THERAPIES FOR PARKINSON'S DISEASE.THE PATIENT-REPORTED OUTCOME CONSORTIUM (PRO) WAS CREATED TO IDENTIFY AND PRIORITIZE THE MEDICAL PRODUCT DEVELOPMENT AREAS WHERE PRO INSTRUMENTS ARE NEEDED, AS WELL AS TO SUBMIT QUALIFICATION DOSSIERS TO REGULATORY AGENCIES FOR QUALIFICATION OF PRO INSTRUMENTS FOR USE IN REGULATORY AND DRUG DEVELOPMENT DECISION MAKING. THE FOLLOWING WORKING GROUPS ARE IN THE PROCESS OF DEFINING PLANS AND ADJUSTING BUDGETS FOR ITS QUANTITATIVE PILOT STUDY: ASTHMA WORKING GROUP, DEPRESSION WORKING GROUP, AND IRRITABLE BOWEL SYNDROME WORKING GROUP. TWO WORKING GROUPS, FUNCTIONAL DYSPEPSIA AND NON-SMALL CELL LUNG CANCER ARE CONTINUING THE WORK TO COMPLETE THE QUALITATIVE RESEARCH PHASE OF EACH PROJECT. THE COGNITION WORKING GROUP IS ABOUT TO BEGIN ITS WORK ON THE NEXT PHASE TO FURTHER DEVELOP, REFINE, AND EVALUATE THE DRAFT TO SUPPORT THE REGULATORY QUALIFICATION PROCESS. THE RHEUMATOID ARTHRITIS WORKING GROUP AWAITS THE RESULTS OF THE LITERATURE REVIEW CONDUCTED BY OMERACT IN ORDER TO INFORM ITS NEXT STEP OF THE PROJECT.THE PREDICTIVE SAFETY TESTING CONSORTIUM (PSTC) COMPILES, GENERATES, AND SUBMITS FOR REGULATORY REVIEW DATA ON NEW SAFETY BIOMARKERS TO BE USED IN DRUG DEVELOPMENT, THUS ADVANCING THE DRUG SAFETY ASSESSMENT PROCESS. THE FDA AND EMA HAVE ISSUED "LETTERS OF SUPPORT" ON THE KIDNEY SAFETY BIOMARKERS TO ENCOURAGE THEIR USE AND DATA COLLECTION FOR ULTIMATE CLINICAL QUALIFICATION. STUDIES ARE ONGOING TO MONITOR THE BIOMARKERS' PERFORMANCE IN PATIENTS WHO ARE ALREADY BEING MONITORED DUE TO NECESSARY TREATMENT WITH POTENTIALLY TOXIC THERAPIES AND ARE BEING RUN IN CONJUNCTION WITH THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. THE SKELETAL MUSCLE WORKING GROUP HAS COMPLETED THEIR RESEARCH AND EVALUATION AND IS PREPARING TO PRESENT THEIR INFORMATION TO THE FDA TO GARNER A LETTER OF SUPPORT. WORK IS ALSO UNDERWAY TO ASSESS THE VALUE OF PRECLINICAL BIOMARKERS TO DETECT DRUG INDUCED INJURY IN THE LIVER, VASCULAR AND TESTICULAR SYSTEMS, AND DRUG INDUCED CARDIAC HYPERTROPHY. A NEW EFFORT TO LOOK AT BILE SALT EXPORT PUMP INHIBITION AS A NEW BIOMARKER OF LIVER TOXICITY.THE CRITICAL PATH TO TB REGIMENS (CPTR) IS COLLABORATION WITH THE BILL AND MELINDA GATES FOUNDATION AND THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT. THE GOAL OF THIS COLLABORATION IS TO SIGNIFICANTLY SPEED DEVELOPMENT OF INNOVATIVE TREATMENT REGIMENS FOR TUBERCULOSIS. THE BIOMARKER AND CLINICAL ENDPOINT WORKING GROUP MET WITH THE FDA, AND WITH FDA'S SUPPORT AND ENCOURAGEMENT, ARE WORKING TO INCLUDE THE USE OF QUANTITATIVE LIQUID CULTURE RESULTS FOR DETERMINING TREATMENT SUCCESS OR FAILURE IN THE TB THERAPY DEVELOPMENT GUIDANCE. THE EMA SAWP HAS ISSUED A POSITIVE OPINION ABOUT A HOLLOW FIBER MODEL FOR USE TO SELECT DRUG REGIMENS, AND INFORM DOSING DECISIONS. WORK IS ONGOING TO HELP DEVELOP A RAPID DRUG SENSITIVITY TEST TO AID IN INFORMING APPROPRIATE TREATMENT DECISIONS FOR PATIENTS THAT HAVE DRUG RESISTANT FORMS OF TB. SEVERAL TB MODELING EFFORTS ARE UNDERWAY FROM A PHYSIOLOGICALLY-BASED PHARMACODYNAMIC MODEL TO A POPULATION-BASED DISEASE PROGRESSION MODEL TO AID IN THE UNDERSTANDING THE DISEASE AND FACILITATE THE DESIGN OF NEW CLINICAL TRIALS. A NEW DATABASE PLATFORM IS IN DEVELOPMENT TO STORE AND ANALYZE GENOTYPIC AND PHENOTYPIC DATA TO DETERMINE WHICH TB STRAINS ARE RESISTANT TO WHICH DRUGS. A PARTNERSHIP WITH THE POLYCYSTIC KIDNEY DISEASE (PKD) FOUNDATION TO QUALIFY TOTAL KIDNEY VOLUME (TKV) AS A PROGNOSTIC BIOMARKER FOR PKD HAS MADE SIGNIFICANT PROGRESS. THE CDISC DATA STANDARD IS COMPLETE WHICH HAS ENABLED A DATABASE TO BE CREATED FROM REGISTRY DATA FROM THREE ACADEMIC INSTITUTIONS AND TWO NIH STUDIES. IT CONTAINS LONGITUDINAL DATA ON OVER 2800 PKD PATIENTS. THE DATA HAS BEEN ANALYZED AND A BRIEFING PACKAGE WAS SUBMITTED TO BOTH THE FDA AND EMA. FINAL QUALIFICATION PACKAGES HAVE BEEN SUBMITTED TO THE FDA AND EMA AND THE CONSORTIUM IS WAITING FOR FINAL APPROVAL. A LETTER OF SUPPORT FOR TKV WAS ISSUED BY THE FDA, AND A DRAFT OPINION IN SUPPORT OF TKV WAS ISSUED BY EMA. THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENT CONSORTIUM COLLABORATION HAS DEVELOPED AND PUBLISHED A NEW CDISC DATA STANDARD FOR MS AND HAS CREATED AN MS DATABASE. ADDITIONAL DATA HAS BEEN RECEIVED, REMAPPED, AND ADDED TO THE DATABASE WITH APPROXIMATELY 16,000 PATIENT RECORDS HAVE BEEN RECEIVED. WORK IS ONGOING TO DEVELOP AND QUALIFY A NEW IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT WITH THE FDA AND EMA FOR USE IN NEW CLINICAL TRIALS. A STATISTICAL ANALYSIS PLAN HAS BEEN SUBMITTED TO BOTH THE FDA AND EMA.AT THE REQUEST OF THE FDA, A NEW INTERNATIONAL NEONATAL CONSORTIUM HAS BEEN LAUNCHED. THIS CONSORTIUM IS DEDICATED TO THE UNIQUE CHALLENGES INVOLVED WITH DEVELOPING AND TESTING THERAPIES IN NEW BORN BABIES. TWO IMPACTFUL WORKSHOPS WERE HELD THIS YEAR AND THE INITIAL GOALS OF THE CONSORTIUM HAVE BEEN ESTABLISHED. 11136489 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 24 0 1 49 1 0 0 0 0 0 0 0 0 0 0 X 16 15 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AZ X STEVE BROADBENT 5206478382 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 857185898 LYLE J BOOTMAN PHD SCD BOARD MEMBER 1.00 X 0 0 0 D CRAIG BRATER MD BOARD MEMBER 1.00 X 0 0 0 M WAINWRIGHT FISHBURN JR BOARD MEMBER 1.00 X 0 0 0 THE HONORABLE JAMES C GREENWOOD BOARD MEMBER 1.00 X 0 0 0 MICHAEL KASSER MBA PHD BOARD MEMBER 1.00 X 0 0 0 SHAUN A KIRKPATRICK MA BOARD MEMBER 1.00 X 0 0 0 THE HONORABLE JAMES T KOLBE BOARD MEMBER 1.00 X 0 0 0 RICHARD T MYERS JR BOARD MEMBER 1.00 X 0 0 0 CINDY PARSEGHIAN MBA BOARD MEMBER 1.00 X 0 0 0 ALASTAIR JJ WOOD MB CHB BOARD MEMBER 1.00 X 0 0 0 TIMOTHY R FRANSON MD BOARD MEMBER 1.00 X 0 0 0 PETER BARTON HUTT LLB LLM BOARD MEMBER 1.00 X 0 0 0 ALAN G LEVIN MS CPA BOARD MEMBER 1.00 X 0 0 0 PAULA OLSIEWSKI PHD BOARD MEMBER 1.00 X 0 0 0 PETER B CORR MD PHD CHAIRMAN OF THE BOARD 1.00 X X 0 0 0 JEFFREY E JACOB SM VICE CHAIRMAN 1.00 X X 0 0 0 MARTHA A BRUMFIELD PHD CHIEF EXECUTIVE OFFICER 40.00 X X 296330 0 20771 STEVEN T BROADBENT MBA CHIEF OPERATING OFFICER & TREASURER 40.00 X 184908 0 22992 ENRIQUE AVILES SECRETARY 40.00 X 160535 0 22706 LYNN D HUDSON PHD CHIEF SCIENCE OFFICER 40.00 X 189410 0 15227 JOHN-MICHAEL SAUER PHD EXECUTIVE DIRECTOR PSTC 40.00 X 177575 0 27506 STEPHEN JOEL COONS PHD EXECUTIVE DIRECTOR PRO 40.00 X 174576 0 18872 DEBRA HANNA PHD EXECUTIVE DIRECTOR CPTR 40.00 X 160009 0 21871 DIANE STEPHENSON PHD EXECUTIVE DIRECTOR CAMD 40.00 X 161942 0 22947 1505285 0 172892 10 0 1 0 ADELPHI VALUES ADELPHI MILL BOLLINGTON CHESIRE UK SK105JB RESEARCH 430587 HEALTH RESEARCH ASSOCIATES 6505 216TH STREET SW SUITE 105 MOUNTLAKE TERRACE WA 98043 RESEARCH 283598 RTI HEALTH SOLUTIONS PO BOX 14688 RESEARCH TRIANGLE PARK NC 27709 RESEARCH 253142 PHARSIGHT CORPORATION PO BOX 200854 PITTSBURGH PA 15251 SOFTWARE AND STATISTICAL MODEL 243253 EPHIBIAN 3180 N SWAN ROAD TUCSON AZ 85712 SOFTWARE DEV, WEB AND INFO SECURITY 172270 7 3661773 6608037 10269810 RESEARCH SUPPORT FEES 541700 3644500 3644500 OTHER REVENUE 900099 71280 71280 3715780 13587 13587 69216 0 69216 69216 69216 400 0 400 400 400 14068793 3715780 0 83203 X 3684743 3684743 731985 471537 260448 3365374 2311158 1054216 233556 161250 72306 328694 230104 98590 274690 187229 87461 49962 47654 2308 128115 96138 31977 60275 41083 19192 2318185 2289486 28699 126119 88508 37611 202385 170206 32179 331073 304811 26262 386154 172870 213284 445272 428542 16730 353871 336067 3666 14138 74532 51159 23373 39227 26737 12490 DUES AND SUBSCRIPTIONS 33054 29391 3663 0 MISCELLANEOUS 10672 7816 2856 0 13177938 11136489 2027311 14138 2377814 2758599 8050439 7214664 556585 403661 677052 438101 38074 37395 922984 801673 163401 121311 3374260 4727502 15471 15471 15253096 15716704 572234 1167646 10787286 9764627 11359520 10932273 X 3877914 4784431 15662 0 3893576 4784431 15253096 15716704 890855 0 X 0 1 X 1 1 1 X 7857830 7998908 5915630 5370782 10269811 37412961 7857830 7998908 5915630 5370782 10269811 37412961 7515946 29897015 34431 22660 21279 70230 82059 230659 30697 20745 51442 37695062 13954726 0.79310 0.93190 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 67262 67262 13117663 13184925 809246 202312 0 0 670322 617482 551743 809246 2648793 3973190 109805 60071 60221 67262 297359 167581 154371 137936 202312 662200 993300 PART II-A, LINE 1B C-PATH EXPENDS A MINOR AMOUNT OF TIME AND RESOURCES TO EDUCATE MEMBERS OF CONGRESS IN THE AREA OF DRUG DEVELOPMENT. C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. THIS YEAR C-PATH EXPENDED $60,274 IN THIS EFFORT. 171507 128168 43339 249206 236731 12475 502271 436774 65497 121311 X 14068793 0 14068793 0 14068793 13177938 0 13177938 0 13177938 PART X, LINE 2: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR FEDERAL AND STATE INCOME TAXES IS MADE IN THE FINANCIAL STATEMENTS. INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS ONLY SUBJECT TO INCOME TAXES ON UBTI AS APPLICABLE. AS A RESULT, C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. WITH LIMITED EXCEPTIONS, C-PATH IS NO LONGER SUBJECT TO TAX EXAMINATION FOR ANY YEARS EARLIER THAN 2012 FOR FEDERAL AND 2011 FOR STATE. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX RETURNS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. 1 BAYLOR RESEARCH INSTITUTE 1950 N STEMMONS FREEWAY SUITE 5010 LOCKBOX 846275 DALLAS TX 75207 751921898 501(C)(3) 1294000 DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 STATE OF TEXAS 1277055 DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET BOX 0897 SAN FRANCISCO CA 94143 946036493 STATE OF CALIFORNIA 513700 DEVELOP A DISEASE PROGRESSION MODEL FOR TUBERCULOSIS UNIVERSITY OF FLORIDA PO BOX 113001 GAINSVILLE FL 32611 596002052 STATE OF FLORIDA 93060 TO DEVELOP A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL FOR TUBERCULOSIS. CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM PO BOX 2068 ROUND ROCK TX 78680 043503931 501(C)(3) 506928 DEVELOP CLINICAL DATA STANDARDS 5 PART I, LINE 2: CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. X X X X X 0 0 0 0 0 0 0 0 0 MARTHA A BRUMFIELD PHD CHIEF EXECUTIVE OFFICER 296330 0 0 0 0 0 14685 0 6086 0 317101 0 0 0 STEVEN T BROADBENT MBA CHIEF OPERATING OFFICER & TREASURER 184908 0 0 0 0 0 13133 0 9859 0 207900 0 0 0 ENRIQUE AVILES SECRETARY 160535 0 0 0 0 0 12812 0 9894 0 183241 0 0 0 LYNN D HUDSON PHD CHIEF SCIENCE OFFICER 189410 0 0 0 0 0 13133 0 2094 0 204637 0 0 0 JOHN-MICHAEL SAUER PHD EXECUTIVE DIRECTOR PSTC 177575 0 0 0 0 0 14267 0 13239 0 205081 0 0 0 STEPHEN JOEL COONS PHD EXECUTIVE DIRECTOR PRO 174576 0 0 0 0 0 12997 0 5875 0 193448 0 0 0 DEBRA HANNA PHD EXECUTIVE DIRECTOR CPTR 160009 0 0 0 0 0 12805 0 9066 0 181880 0 0 0 DIANE STEPHENSON PHD EXECUTIVE DIRECTOR CAMD 161942 0 0 0 0 0 13057 0 9890 0 184889 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 J. LYLE BOOTMAN IS A DIRECTOR AND SHAUN A. KIRKPATRICK IS BOTH AN OFFICER AND DIRECTOR OF RESEARCH CORPORATION TECHNOLOGIES, INC. MIKE KASSER IS AN INVESTOR IN CANCER PREVENTION PHARMACEUTICALS OF WHICH JEFF JACOB IS THE CEO. ALAN LEVIN IS ON THE ADVISORY BOARD OF AUVEN THERAPEUTICS OF WHICH PETER CORR IS A MANAGING PARTNER, AND ALAN LEVIN IS AN INVESTOR IN ADC THERAPEUTICS FOR WHICH PETER CORR IS CHAIRMAN OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S COMPTROLLER, COO, PRESIDENT/CEO, AN OUTSIDE CPA, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. THE CEO'S SALARY HAS REMAINED CONSTANT SINCE THE TIME OF HER HIRE. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. FORM 990, PART IX, LINE 11G RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,635,123. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,635,123. CONSULTING: PROGRAM SERVICE EXPENSES 549,226. MANAGEMENT AND GENERAL EXPENSES 25,956. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 575,182. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 105,137. MANAGEMENT AND GENERAL EXPENSES 2,743. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 107,880. THE CRITICAL PATH FOUNDATION 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 204780896 RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE AZ 501(C)(3) 11 CRITICAL PATH INSTITUTE 1 CRITICAL PATH GLOBAL LTD 20-22 BEDFORD ROW LONDON UK WC1R 4JS FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY UK CRITICAL PATH INSTITUTE 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0